A case of type B insulin resistance syndrome with postprandial hyperglycemia successfully treated with liraglutide

Satoru Uchida, Mina Yamaguchi, Hiromi Hasegawa, Noriaki Ohkiba, Ryotaro Bouchi, Isao Minami, Yoshihiro Ogawa

Research output: Contribution to journalArticle

Abstract

We herein report a patient with type B insulin resistance in whom liraglutide significantly improved postprandial hyperglycemia that had been highly resistant to other treatments, including insulin therapy. The patient was a 73-year-old Japanese male whose hyperglycemia had worsened rapidly after being diagnosed as diabetes. His fasting plasma glucose was 77 mg/dL, HbA1c was 8.6 %, and serum insulin level was 366 /μU/mL. As anti-insulin receptor antibody was detected, we diagnosed the patient with type B insulin resistance. CGM (Continuous Glucose Monitoring) showed that liraglutide reduced the average blood glucose level from 124 mg/dL (standard deviation [SD] 59 mg/dL) to 80 mg/dL (SD 16 mg/dL) by improving the postprandial hyperglycemia and did not increase the time in a hypoglycemic state (27 % to 23 %). The meal tolerance test showed that liraglutide significantly enhanced the reactivity of the plasma insulin responses after food intake. Liraglutide was also effective as a treatment when the patient's postprandial hyperglycemia worsened again, in parallel with increasing inhibited insulin receptor rates. Our findings in this case imply the specific effect of liraglutide in improving type B insulin resistance complicated with postprandial hyperglycemia.

Original languageEnglish
Pages (from-to)244-252
Number of pages9
JournalJournal of the Japan Diabetes Society
Volume60
Issue number3
Publication statusPublished - Jan 1 2017
Externally publishedYes

Fingerprint

Hyperglycemia
Insulin Resistance
Insulin Receptor
Insulin
Insulin Antibodies
Glucose
Hypoglycemic Agents
Meals
Blood Glucose
Fasting
Therapeutics
Eating
Liraglutide
B-insulin
Serum

All Science Journal Classification (ASJC) codes

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

A case of type B insulin resistance syndrome with postprandial hyperglycemia successfully treated with liraglutide. / Uchida, Satoru; Yamaguchi, Mina; Hasegawa, Hiromi; Ohkiba, Noriaki; Bouchi, Ryotaro; Minami, Isao; Ogawa, Yoshihiro.

In: Journal of the Japan Diabetes Society, Vol. 60, No. 3, 01.01.2017, p. 244-252.

Research output: Contribution to journalArticle

Uchida, S, Yamaguchi, M, Hasegawa, H, Ohkiba, N, Bouchi, R, Minami, I & Ogawa, Y 2017, 'A case of type B insulin resistance syndrome with postprandial hyperglycemia successfully treated with liraglutide', Journal of the Japan Diabetes Society, vol. 60, no. 3, pp. 244-252.
Uchida, Satoru ; Yamaguchi, Mina ; Hasegawa, Hiromi ; Ohkiba, Noriaki ; Bouchi, Ryotaro ; Minami, Isao ; Ogawa, Yoshihiro. / A case of type B insulin resistance syndrome with postprandial hyperglycemia successfully treated with liraglutide. In: Journal of the Japan Diabetes Society. 2017 ; Vol. 60, No. 3. pp. 244-252.
@article{4f1595bfea2844db9b2a9018884652bd,
title = "A case of type B insulin resistance syndrome with postprandial hyperglycemia successfully treated with liraglutide",
abstract = "We herein report a patient with type B insulin resistance in whom liraglutide significantly improved postprandial hyperglycemia that had been highly resistant to other treatments, including insulin therapy. The patient was a 73-year-old Japanese male whose hyperglycemia had worsened rapidly after being diagnosed as diabetes. His fasting plasma glucose was 77 mg/dL, HbA1c was 8.6 {\%}, and serum insulin level was 366 /μU/mL. As anti-insulin receptor antibody was detected, we diagnosed the patient with type B insulin resistance. CGM (Continuous Glucose Monitoring) showed that liraglutide reduced the average blood glucose level from 124 mg/dL (standard deviation [SD] 59 mg/dL) to 80 mg/dL (SD 16 mg/dL) by improving the postprandial hyperglycemia and did not increase the time in a hypoglycemic state (27 {\%} to 23 {\%}). The meal tolerance test showed that liraglutide significantly enhanced the reactivity of the plasma insulin responses after food intake. Liraglutide was also effective as a treatment when the patient's postprandial hyperglycemia worsened again, in parallel with increasing inhibited insulin receptor rates. Our findings in this case imply the specific effect of liraglutide in improving type B insulin resistance complicated with postprandial hyperglycemia.",
author = "Satoru Uchida and Mina Yamaguchi and Hiromi Hasegawa and Noriaki Ohkiba and Ryotaro Bouchi and Isao Minami and Yoshihiro Ogawa",
year = "2017",
month = "1",
day = "1",
language = "English",
volume = "60",
pages = "244--252",
journal = "Journal of the Japan Diabetes Society",
issn = "0021-437X",
publisher = "Japan Diabetes Society",
number = "3",

}

TY - JOUR

T1 - A case of type B insulin resistance syndrome with postprandial hyperglycemia successfully treated with liraglutide

AU - Uchida, Satoru

AU - Yamaguchi, Mina

AU - Hasegawa, Hiromi

AU - Ohkiba, Noriaki

AU - Bouchi, Ryotaro

AU - Minami, Isao

AU - Ogawa, Yoshihiro

PY - 2017/1/1

Y1 - 2017/1/1

N2 - We herein report a patient with type B insulin resistance in whom liraglutide significantly improved postprandial hyperglycemia that had been highly resistant to other treatments, including insulin therapy. The patient was a 73-year-old Japanese male whose hyperglycemia had worsened rapidly after being diagnosed as diabetes. His fasting plasma glucose was 77 mg/dL, HbA1c was 8.6 %, and serum insulin level was 366 /μU/mL. As anti-insulin receptor antibody was detected, we diagnosed the patient with type B insulin resistance. CGM (Continuous Glucose Monitoring) showed that liraglutide reduced the average blood glucose level from 124 mg/dL (standard deviation [SD] 59 mg/dL) to 80 mg/dL (SD 16 mg/dL) by improving the postprandial hyperglycemia and did not increase the time in a hypoglycemic state (27 % to 23 %). The meal tolerance test showed that liraglutide significantly enhanced the reactivity of the plasma insulin responses after food intake. Liraglutide was also effective as a treatment when the patient's postprandial hyperglycemia worsened again, in parallel with increasing inhibited insulin receptor rates. Our findings in this case imply the specific effect of liraglutide in improving type B insulin resistance complicated with postprandial hyperglycemia.

AB - We herein report a patient with type B insulin resistance in whom liraglutide significantly improved postprandial hyperglycemia that had been highly resistant to other treatments, including insulin therapy. The patient was a 73-year-old Japanese male whose hyperglycemia had worsened rapidly after being diagnosed as diabetes. His fasting plasma glucose was 77 mg/dL, HbA1c was 8.6 %, and serum insulin level was 366 /μU/mL. As anti-insulin receptor antibody was detected, we diagnosed the patient with type B insulin resistance. CGM (Continuous Glucose Monitoring) showed that liraglutide reduced the average blood glucose level from 124 mg/dL (standard deviation [SD] 59 mg/dL) to 80 mg/dL (SD 16 mg/dL) by improving the postprandial hyperglycemia and did not increase the time in a hypoglycemic state (27 % to 23 %). The meal tolerance test showed that liraglutide significantly enhanced the reactivity of the plasma insulin responses after food intake. Liraglutide was also effective as a treatment when the patient's postprandial hyperglycemia worsened again, in parallel with increasing inhibited insulin receptor rates. Our findings in this case imply the specific effect of liraglutide in improving type B insulin resistance complicated with postprandial hyperglycemia.

UR - http://www.scopus.com/inward/record.url?scp=85017021537&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85017021537&partnerID=8YFLogxK

M3 - Article

VL - 60

SP - 244

EP - 252

JO - Journal of the Japan Diabetes Society

JF - Journal of the Japan Diabetes Society

SN - 0021-437X

IS - 3

ER -